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This work is a product of the project “My first 48 hours out – comprehensive ap- 
proaches to pre and post prison release interventions for drug users in the criminal 
justice system”. 
 
The project, led by the Frankfurt University of Applied Sciences/Germany, received 
funding from the European Union for the period 2017-2018. It aims at addressing the 
gaps in the continuity of care for long-term drug users in prison and upon release, by 
supporting life-saving interventions for the prevention of overdoses and reduction of 
other risks related to drug use and for the establishment of a treatment path, which 
does not get interrupted upon release. 
 
For prisoners with a history of drug use, in particular opioid use, the risks related to 
drug use, in particular overdose and death are extremely high in the immediate period 
after release due to high rates of relapse and lower opioid tolerance. Much still needs 
to be done in order to ensure that people with a history of drug use are sufficiently 
cared for, when released from prisons. Harm reduction measures need to be in place 
for ex-prisoners to be able to readjust to freedom without relapsing back into prob- 
lematic drug use and extreme risk of fatal overdose when released. 
 
The immediate time after release (“my first 48 hours out”) is a critical time for 
action, when the cooperation between prisons, healthcare providers and NGOs is key 
in ensuring continuity of care and where targeted interventions can save lives from 
overdose and build a path towards engagement into further treatment and rehabilita- 
tion for people who use drugs. 
 
Among other actions, the project wants to promote the implementation of life saving 
interventions in prison and upon release with specific reference to harm reduction, 
overdose prevention and the use of naloxone programmes. 
 
This is a key priority to be addressed by both policy makers and practitioners in 
European countries. The current work aims at producing hands-on guidelines for 
policy makers and practitioners from prison health services on how to promote, 
initiate and manage interventions related to overdose prevention through naloxone 
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BLS - Basic Life Support 
 
CNS – Central Nervous System 
DRD – Drug-related Death 
IM – Intramuscular 
 
IN - Intranasal 
 
NGO - Non-Governmental Organisation 
NNP – National Naloxone Programme  
OAT – Opioid Agonist Treatment 
PGD – Patient Group Direction 
POM – Prescription Only Medicine 
SDF – Scottish Drugs Forum 
THN – Take-Home Naloxone 
 









These guidelines are relevant to prisoner healthcare policy makers, managers and 
practitioners involved in caring for people who use drugs and those likely to witness 
an overdose. 
 
The objective of these guidelines is to assist in the reduction of opioid-related mor- 
tality within the first few weeks following prison release. Specifically these guidelines 
seek to: 
 
- increase the availability of naloxone to people likely to witness an overdose 
when they are released from prison 
 
- increase awareness of the identification of the signs and symptoms of an 
overdose and equip people with the skills to respond effectively 
 
In order to achieve these outcomes, these guidelines will: 
 
- inform prisoner healthcare policy makers of the benefits of naloxone-on-re- 
lease from prison 
 
- advise policy makers of the practical steps necessary to introduce nalox- 
one-on-release 
 
- inform programme managers of the benefits of naloxone-on-release and 
provide advice on implementation 
 
These guidelines are intended to be straightforward and user-friendly, in order that 










Globally, overdose is a leading cause of premature death among people who inject 
drugs and the overwhelming majority of overdose fatalities involve opioids*. World- 
wide, an estimated 69 000 people die from opioid overdose each year (WHO, 2014). 
 
Data collection, monitoring and pathology vary across Europe with between 6,300 and 
8,000 drug-induced deaths reported each year (EMCDDA, 2016a). The true number is 
likely to be much higher. 
 
Research has shown that the majority of these deaths are accidental and therefore 
preventable, with a large proportion of overdoses being witnessed by other people. 
 
Opioids depress the central nervous system (CNS) and can contribute to life-threat- 
ening respiratory depression, particularly when taken in combination with other CNS 
depressants, such as benzodiazepines and alcohol. 
 
Opioids affect the part of the brain that instructs the lungs to breathe, so when 
someone is experiencing an overdose the breathing is reduced until it stops altogeth- 
er. 
 
Non-fatal overdoses are also a major cause for concern as people can experience dev- 
astating and sometimes life-changing consequences due to injury and/or impairment, 
whilst also increases their chances of a future fatal overdose. It is estimated that 
in Europe, for every fatal overdose there are 20-25 non-fatal overdoses (EMCDDA, 
2010). So even by using the lower estimate and reported deaths, that would be 
126,000 every year. 
 
*Opioids and opiates are used interchangeablly throughout this document 
 
What puts people at risk of overdose? 
The main risk factors for overdose are: 
 
Reduced tolerance –tolerance to a drug can decrease rapidly (often within a few days) 
when a person has ceased using a drug. Therefore high risk times for overdose will 
include release from prison/custody, discharge from hospital, following residential 
rehab or cessation of opioid agonist treatment. 
 
Polydrug use–using a combination of different drugs (not necessarily at exactly the 
same time) and in particular a range of CNS depressants. Due to the action of long 
and short-acting drugs, people can still be ‘mixing drugs’ even if they are not taken 
on the same day in some instances. Long-acting drugs may be present in the body for 
several days. 
 
Other factors such as poor physical health, mental health and social factors can also 




What can be done to prevent an overdose? 
 
Whilst these guidelines will focus on an intervention to prevent an overdose becoming 
a fatality, it is important to consider what could be done to prevent an overdose occur- 
ring in the first place. 
 
It has been well researched and evidenced that treatment is a protective factor. 
Optimal dosing and duration of opioid agonist treatment must be provided in order to 
make an impact on reducing drug-related deaths (EMCDDA, 2016b). 
 
Providing information and having discussions about overdose risks are essential. It is 
important not to assume that people who have been using drugs for a long time have 
accurate information, as these assumptions often result in such conversations not 
taking place. 
 
Who is likely to witness an overdose? 
People most likely to witness an overdose are people who use drugs. Others will 
include family members, friends, staff working in drug services, homeless service 
staff, hostel staff, outreach workers, law enforcement...literally anyone who is in 
contact with people who use drugs - the list is endless. 
 
What are the signs and symptoms of an overdose? 
So many people die because it was not recognised that they were experiencing an 
overdose. Interventions to reverse an overdose are redundant if the overdose has not 
been identified. It is very common that people will assume that the person who has 
overdose is asleep because they appear to be snoring and therefore it is crucial that 







- Person is unresponsive 
 
- Person has slow/shallow/rasping breathing (often mistaken for snoring) 
 
- Person has pale skin and may have blue lips (cyanosis) 
 
- Person has pinpoint (constricted) pupils (indicates that opiates have been 
consumed) however opiate overdose should not be ruled out if pinned pupils 
are not present 
 
In the majority of cases, death will not occur instantaneously. Many deaths happen 
two or three hours after drug use. Only one-quarter of deaths happen immediately 
after drug administration. This timeframe provides an opportunity for intervention. 
 
The majority of witnesses actively intervene to address the emergency, but many of 
their actions tend to be incorrect and ineffective (slapping their collapsed companion, 
walking them around, etc.). In research interviews with people who had experienced 
or witnessed an overdose, only half had called for an ambulance; their principal 
reasons for not doing so were fear of police involvement and belief that they could 
handle the situation themselves (Wakeman et al. 2009). 
 
Harm reduction advice for people who use opiates 
- Be aware of your tolerance (if you haven’t used for a while) and take a ‘test 
dose’ first 
 
- Consider smoking rather than injecting 
 
- Avoid mixing drugs (including prescriptions and alcohol) 
 
- Don’t use alone 
 
- Make sure naloxone is available and that everyone there knows where it is 
and how to use it 
 
- Look out for the signs and symptoms of an overdose 
 









Naloxone is a medication that reverses the effect of opioids. In an emergency overdose 
situation it can be a lifesaver. 
 
The medication itself has been around for over 50 years, is on the World Health Or- 
ganisation’s (WHO) list of essential medicines and more recently was recommended 
in WHO guidelines for the community management of opioid overdose. The practice 
of putting naloxone in the hands of people most likely to witness an overdose (people 
who use drugs) began in the 90’s. 
 
How it works 
Naloxone works by temporarily displacing the opioids from the receptors in the brain to 
reverse the breathing difficulties being experienced by the person who has overdosed 
(EMCDDA, 2016a). When administered by intramuscular injection this only takes a few 
minutes although several doses may be required depending on the person’s response 
and the opioid involved. 
 
It is a ‘competitive antagonist’ which means that it competes with opioids for the 
receptors and then blocks them temporarily. So it does not cause any kind of ‘high’ or 
intoxication, its only job is to reverse the effects of respiratory depression caused by 
opioids. 
 
Opioids include methadone, codeine, tramadol, fentanyl and morphine amongst 
others, so it is not only for use in suspected heroin overdoses. 
 
If the person who has overdosed is physically dependent on opioids they may experi- 
ence acute withdrawal syndrome following naloxone administration, the risk of which 
increases with the amount of naloxone that has been administered. 
 
Naloxone is very short-acting and the effects will begin to wear off after 
20-30 minutes, after which the opioids will re-attach to the receptors. It 
is very important that the person does not use any further drugs while the 
naloxone is active as when it wears off they would likely overdose again. 
 
Naloxone is an extremely safe medication. 
 
When it should be given 
Naloxone is for ‘suspected’ opiate overdose not confirmed. If there are signs of an 
overdose, it is perfectly safe to administer naloxone to someone even if it turns out 
they have not consumed opiates, although it would be ineffective in reversing the 
effects of any other drugs such as alcohol, benzodiazepines or cocaine, although they 





In Europe, naloxone has only been licensed for intramuscular, intravenous and subcu- 
taneous use until recently. A licensed intranasal formulation has now been approved 
for use in the European Union, similar to the ones that have been introduced in the 
United States and Canada. It is a nasal spray (Nyxoid) available in single-dose con- 
tainers (1.8mg) and the recommended dose is one spray into one nostril. At the time 
of writing, it is not currently being used in any European country and is not yet 
available in the UK. 
 
In some countries, such as Norway and Germany, a nasal atomiser is attached to a 
pre-filled syringe of naloxone 1mg/ml and administered intranasally off-license rather 
than by injection. 
 
Ampoules or vials and pre-filled syringes of naloxone hydrochloride are available in dif- 
ferent concentrations: 0.02 mg, 0.4 mg and 1 mg per 1 ml vials, 2 mg/1 ml, 2 mg/2 
ml, 2 mg/5 ml prefilled syringes, and a 4 mg/10 ml multi-dose vial. 
 
Dosing will depend on which product is chosen but in most cases 0.4–0.8 mg is an 
effective dose. It is important to provide sufficient naloxone to supplement the initial 
dose, as necessary (WHO, 2014). 
 
In France, the nasal spray that has been adopted off-license is a dose of 0.9mg/0.1 
ml administered in each nostril, repeated after few minutes, with a total of 4 x 0.9mg 
doses. 
 
In the UK, naloxone is provided in a 2mg/2ml pre-filled syringe with two needles for 
intramuscular administration. Doses of 0.4mg are given every 2-3 minutes until the 









The legal situation varies across Europe and gives an unclear picture. It has been described 
well in the EMCDDA publication ‘Preventing opioid overdose deaths with take-home 
naloxone’. 
 
In the EU, naloxone is currently only licensed for injection, meaning it is usually a pre- 
scription only medicine, which is why the legalities can create obstacles for take-home 
naloxone programmes. 
 
The main challenges are that possession or use of naloxone could be considered an 
offence in some countries and there is also some concern regarding liability should the 
person who has overdosed come to additional harm or if they were to die following the 
administration of naloxone. 
 
Currently, several European countries manage this with a ‘legal code’ that protects first 
responders. 
 
These obstacles may be alleviated with the introduction of licensed intranasal products 
in the near future. 
 
Example from France 






Firstly, a Temporary Cohort Use Authorisation (ATUc) from the French 
National Agency for the Safety of Health Products (ANSM, the French drug 
agency) for the NALSCUE® product (naloxone nasal spray from Indivior), 
was authorised on 5th November, 2015 and was made available from 26th 
July, 2016. 
 
The ATUs allow a therapeutic treatment of which efficacy and safety of use 
are strongly presumed, to be dispensed in a controlled manner for a de- 
fined population with the authorisation of the ANSM, pending a marketing 
authorisation that the pharmaceutical company undertakes to request. 
 
The ATUc allows treatment to be made available before the marketing au- 
thorisation, but with inclusion by a doctor, delivery of treatment by a hos- 
pital pharmacy, and provision of medical follow-up data to be transmitted 
by the prescriber to the pharmaceutical company, which communicates 
them to the ANSM. 
 







In the UK, a change was made to the Medicines Act in 2005 which added naloxone to 
a list of medications that can be administered, by injection, by anyone for the purpose 
of saving a life. Because of its Prescription Only Medicine (POM) status it is not avail- 
able over the counter and was initially supplied using a Patient Group Direction (PGD) 
or in some cases a prescription however, due to a regulation change in October 2015, 
it is now much more widely available and accessible without the need for a PGD or 
prescription. 
 
PGDs, similar to Standing Orders used in some countries, are written instructions 
(signed by a doctor and a pharmacist) to allow the supply or administration of POMs 
by nurses and pharmacists without the need for an individual prescription from a doc- 
tor. 
 
Naloxone can be supplied to anyone who is likely to witness an overdose which in- 
cludes family members, friends, staff working in services in contact with people who 
use drugs and most importantly, people who use drugs. 
 
logic care settings (medico-social settings called CSAPA, the most common 
specialised settings in the community with more than 450 centers through- 
out France), emergency services, hospital addiction unit, Addiction Care 
and Liaison Teams (ELSA) in hospitals, penitentiary health units as well as 
by centres and structures with mobile care teams for people in a precarious 
or excluded situation managed by non-profit organisations. 
 
ATUc limitations: Harm reduction settings (called CAARUDs in France: 
Centres d’ Accueil et d’ Accompagnement à la réduction des risques pour 
les usagers de Drogues) are not authorised for regulatory reasons within 
the framework of the ATUc to dispense naloxone despite their crucial role 
in preventing harms among active drug users. The main reason is that they 





Within the framework of the marketing authorisation: The ANSM issued a 
marketing authorisation for NALSCUE®(naloxone 0.9mg/0.1 ml) on 28th 
July 2017. Discussion on the price of the product is ongoing. 
 
Once the discussion on the price of the drug and reimbursement rate is 
complete, NALSCUE® will then be available as a non-mandatory prescrip- 
tion treatment, with dispensing to patients who have received specific 
training in its use. This is already the case for patients who have been 
included in the ATU NALSCUE® protocol, but training of users and profes- 
sionals must continue. 
 
In addition to the previous settings, CAARUDs will be allowed to deliv- 
er naloxone to the people they follow, provided that staff are trained to 





The supply is no longer restricted to nurses/pharmacists and can now be provided by 
anyone working in a drugs service. 
 
In Italy, from 1991, the practice of distributing THN was initiated when doctors took 
the responsibility to allow the harm reduction staff to do so in response to the rising 
numbers of drug-related deaths (Ronconi et al. 2016). 
 
Naloxone was then formally classified as an over-the-counter drug in 1996 by the 
Minister of Health. This means it is now sold in pharmacies without the need for a pre- 
scription, available to anyone and pharmacies are obliged to have it available as it is a 
life-saving medication. 
 
The legislation in the Italian Penal Code is also very clear about lay people being 
first responders. This is covered by two articles – emergency situations and omission 
of first aid. Essentially, lay people are covered legally by administering naloxone to 
someone who appears to be in a life-threatening condition and may indeed face pros- 









There are a limited number of published papers on the subject of naloxone-on-release 
within European countries. A mapping review conducted (Horton et al. 2017) showed 
that the majority of papers looked at attitudes towards naloxone-on-release and were 
mainly from the USA or the UK. 
 
The information below has been taken mainly from these limited published papers and 
from the EMCCDA report (EMCDDA, 2016a) and also gives a brief highlight of commu- 
nity distribution in Europe. 
Norway 
The community intranasal naloxone programme, commenced in Oslo and Bergen in 
2014, has previously been unable to implement on a large scale within the prison set- 
ting. As the programme expands, emphasis on establishing within prisons is a priority. 
In Norway the programme provides a pre-filled naloxone syringe (2mg/2ml) with a 
nasal atomiser rather than needles for injection. 
 
A study conducted inside prisons was completed to assess the impact of brief overdose 
prevention training. It assessed the knowledge of prisoners in Oslo pre and post nalox- 
one training (Petterson and Madah-Amiri, 2017). 
 
Participants were found to have a high baseline knowledge of risk factors, symptoms 
and care regarding opioid overdoses. However the brief training significantly improved 
knowledge, particularly in relation to naloxone. 
 
They concluded that the need for overdose prevention programmes is critical and that 
naloxone training provided in the prison setting may improve the ability of inmates to 
recognise and manage opioid overdoses after their release. 
 
Estonia 
In Estonia, as well as having a community based programme (launched in 2013), from 
2015 naloxone began being issued by medical departments within prisons. These pris- 
ons organise training for inmates with previous experience of IV opioid use before they 
are released from prison and upon release, give them a pre-filled naloxone syringe kit 
to take home. 
 
From June 2015 to the end of 2016, a total of 107 inmates received relevant training 
in Viru Prison, Harku and Murru Prison, and Tartu Prison; 85 pre-filled naloxone syring- 
es were issued to inmates upon release. 
 
England, UK 
In 2008, the UK Medical Research Council awarded funding for the N-ALIVE pilot trial. 
Any prison inmate of at least 18 years of age, with a minimum duration of imprison- 




the trial, which started in May 2012. Participants from 16 prisons in England were 
randomised to participate in the N-ALIVE trial. 
 
Upon release from prison, those randomised to the take-home naloxone arm would 
receive an N-ALIVE wallet containing a pre-filled naloxone syringe and an instruction 
leaflet, as well as a DVD containing video instructions on overdose management and 
naloxone administration. 
 
Study subjects in the control group learnt, at the point of their release, that the 
N-ALIVE wallet given to them contained no naloxone. 
 
Randomisation to the N-ALIVE trial ended on 8 December 2014, partly due to the evi- 
dence from Scotland’s national naloxone programme (EMCDDA, 2016a). 
Ireland 
Commencing in 2015, 31 individuals were trained as trainers with close to 600 taking 
part in multi-agency training sessions for the naloxone demonstration project (Health 
Service Executive, 2016). 
 
95 prescriptions of THN were issued during the project by 6 GPs in Dublin and Limer- 
ick. 
 
5 potentially fatal overdoses were prevented with THN which was administered on 4 
occasions by staff and once by a peer. 
 
The Irish prison service participated in the roll out of the training and delays regarding 
prescribing were experienced but resolved towards the end of the project. 
Denmark 
Intranasal naloxone distribution started in 2013 in Copenhagen, Aarhus, Odense and 
Glostrup. As of 2014, 121 people who use drugs had received overdose prevention 
training and THN kits (EMCDDA, 2016a). 
 
THN is provided to people who use drugs, family members, friends and staff working 
in services. Training is provided on overdose prevention and management before peo- 
ple are provided with a THN kit. 
 
The kit is a 2mg/2ml pre-filled syringe with a separate nasal atomiser. There are 5 
doses of 0.4mg with instructions to administer the first 3 doses intranasally and the 
remaining two by intramuscular injection. 
 
Germany 
“Fixpunkt” Berlin began distributing THN in 1999 but the project did not secure fund- 
ing after the pilot phase in 2002. THN did, however, continue to be provided in lower 
numbers following the pilot (Dichtl et al. 2018; Dichtl and Stöver 2015). 
 
Currently there are approximately 10 initiatives of NGOs providing THN, and also some 
self-help organisations. However, no THN programme is focusing on the period of re- 




THN is now being discussed widely in Germany as well as the development of a net- 
work in order to improve the provision of THN (coordinated by Akzept e.V.; see 
www.naloxoninfo.de). 
Italy 
THN has been available over-the-counter in pharmacies in Italy since the late 80s and 
was distributed as early at 1991 to people who use drugs, their families and friends 
but has never been formally evaluated. 
 
THN forms part of the overdose prevention strategy and is now distributed from 57 
low-threshold harm reduction services although availability can vary regionally, with 
notably the south and the islands lacking in this provision. The majority of THN sup- 
plies are from drop-ins and mobile needle exchanges. As well as being provided by 
workers in these services, there is also a strong peer-to-peer education and supply 
network in operation (Ronconi et al. 2016). 
 
Despite THN being available in pharmacies, the pharmacists themselves do not play an 
active role in distributing it to people who use drugs and this is seen as a shortfall in 
the programme. 
 
In 2015, of the 57 services that distributed THN to their clients, 2 did not provide 
data. The 55 services for which activity data is known, showed a total volume of 
14.999 vials distributed, an average of 272 vials per year. 
 
There are little to no harm reduction services provided in prisons in Italy and this is 
recognised as an area where THN distribution would be valuable. 
 
This research from Italy derived a number of conclusion and recommendations. The 




• The current regulatory framework is clear and sufficient 
• Every service can and should distribute naloxone 
• Provide incentive for the peer support approach, collaboration between 
peers-services and support PWUDs associations 
• Initiate programmes aimed at families 
• Adopt THN in prison and post-prison contexts 
POLICY 
• To have an up-to-date policy and action plan on drugs 
• To release guidelines for Harm Reduction 
• Include THN in the LEA- Essential levels of Assistance 
RESEARCH 
• Include THN in the institutional monitoring system 
• Develop qualitative research, change perception about people who use drugs 
• Develop evaluation studies for the processes and outcomes of THN 
• Greater synergy between information systems and the death registries to 





Barcelona began formally distributing THN in 2008, although there were reports of this 
happening informally since 2001. 
 
The formal programme commenced in 2008 and THN is now provided to people who 
use drugs from a broad range of services including drug treatment services, drug con- 
sumption rooms and detox centres. 
 
Initially there was a financial incentive for people who use drugs to attend training. 
By December 2013, 5830 THN kits had been supplied with 40% reporting having used 
it on someone. 
 
Challenges noted by the programme coordinators include attitudinal barriers from ab- 
stinence-focussed services, limited carriage of naloxone kits and a lack of provision via 
the prison service (EMCDDA 2016a). 
 
UK 
Availability of naloxone in England is improving and is provided in 138 of 151 local au- 
thority areas. However in a recent report (Release, 2017) analysis of the coverage of 
THN in each locality was variable; 
 
Out of 151 local authorities, 117 provided details on the number of take-home nalox- 
one kits given out in the 2016/17 financial year. Among these: 
 
- Nationally, an average of 12 take-home naloxone kits were given out for 
every 100 people using opiates (equivalent to only 12% coverage); 
- Coverage was 0% in 18 areas (including the 13 that did not provide take- 
home naloxone); 
- Coverage was between 1% and 20% in 72 areas; 
- Coverage was between 20% and 49% in 26 areas. 
 
Meanwhile, Wales now has a national programme that commenced in 2009 (as a pilot) 
and up until March 2017, 15037 kits had been supplied to 6302 unique individuals. 
It has been reportedly used 1654 times in overdose situations (Morgan and Smith, 
2017). 
 
There are six male-only prisons located within Wales, three of which provide THN to 
individuals identified at risk upon release. During 2016-17 distribution of THN was suc- 
cessfully implemented within HMP Eastwood Park in Gloucestershire (serving as Wales’ 































































Rates of drug-related deaths in Scotland are among the highest in Europe. In 2016, 
867 people lost their lives to preventable overdose deaths, the majority of which were 
accidental (National Records of Scotland, 2017). 
 
In response to the rising number of opioid-related deaths, the Scottish Government 
introduced a National Naloxone Programme in 2010, which was launched in 2011. 
 
Scotland has a population of approximately 5.2 million people with 14 Health Boards, 
15 Prisons and 30 Alcohol and Drug Partnerships. All 14 of the Health Boards partici- 
pate in the take-home naloxone programme and all 15 Prisons are involved in supply- 
ing naloxone to people on-release. 
 
There are around 61,500 people with problematic drug use in Scotland and in the 
region of 23,255 of those are known to services. Between 22-25,000 people receive 
methadone prescriptions. 
 
Every August, the National Records of Scotland report is published which details the 
number of people who died from a drug-related death the previous year, their ages, 
demographics and the drugs that were implicated in the deaths. From the 2016 fig- 
ures, the average number of people dying in Scotland every year is 659 and the aver- 
age age is 41. 
 
The main drugs involved in the deaths are consistently heroin, methadone, benzodiaz- 
epines and alcohol. In 2016, opiates were implicated in, or potentially contributed to, 
88% of the deaths. 
 
Around 6 months* after the NRS report, Information Services Division (ISD) Scotland 
publishes the Drug Deaths Database report that provides a more detailed picture of 
the individual circumstances surrounding the deaths (Information Services Division 
2016a). 
 
*This has now been changed to a biannual report from 2016. 
 
There are many common themes emerge from this; 
 
- There are often several hours between the overdose and the death 
- The person is likely to have had a previous non-fatal overdose 
- A combination of drugs have been taken 
- Witnesses are present 
- The person is an older (35-44 yrs) drug user with a long history of problematic 
drug use 
- The person is not in treatment, but in a large number of cases has been in 
treatment within 6 months prior to their death 
 
Given that two of the main drugs involved are opioids and that in most cases witness- 
es are present, it makes sense to get naloxone in to the hands of those most 























The need for Critical Incidents 
training to be made available 








Critical Incidents Training 
programme on overdose 
prevention and emergency 
responses launches 
Letter of Comfort from the 
Lord Advocate sought to 
allow naloxone use by non- 
medical staff; this request 
was declined. 
Amendment made to the Medicines 
Act (1968) to allow naloxone to be 
injected “by anyone for the puropse of 
saving life in an emergency” 
Scottish Association of Drug and 
Alcohol Action Teams and SDF write 
to the Medicines and and Healthcare 
Regulatory Agency requesting 
the amendment to legally allow 
naloxone to be administered to lay 
responders 
SDF organises major conference on 
drug deaths 
Scottish Executive launches the 


















The end of funding 
of reimbursement of 
naloxone kits 
Funding responsibility 




UK regulations for 
naloxone amended 
to allow wider 
distribution by relaxing 








coverage should be 
increased to 25% of 
people with a drug 
problem 
UK’s first licensed com- 
munity naloxone pack 
(Prenoxad) launched 
Recommendation that 
coverage of at least 
15% of people with a 










For the first time, the prisons were issued with a 
separate target (previously the target had included 
community and prison figures together). The prison 
target was an annual rather than cumulative target, 
based on the number of prisoners who test positive for 
opiates at reception and the average number of 
liberations each prison has on an annual basis. They 
are expected to supply a minimum of 25% each year. 
2003 2004 2005 















Multi-agency factfinding trip 
from Glasgow to the Chicago 
Recovery Alliance. USA 
Glasgow and Lanarkshire 
naloxone pilots launched 
NHS Highland introduce 




This was an important development for 
the consideration of a take-home 
naloxone programme as now anyone can 
legally administer naloxone to anyone for 
the purpose of saving a life in an 
emergency. 
2006 2007 2009 
First naloxone monitoring 
report published by Informa- 
tion Services Division Scotland 
- reported that there had been 
3445 THN kits supplied during 
2011/12 
First two Naloxone Peer 
Eductaion networks trained 
and established 
Lord Advocate produces 
guidelines to allow the supply 
of naloxone to extend to staff 
working in services 
National Forum on Drug-Related 
Deaths recommend the development of 
local THN programmes 
Scottish Government announce rollout 
of fully funded community and prison 
National Naloxone Programme 
SDF recieve funding to provide training 
element of national programme 
National Naloxone Advisory 
Group established and develops a 
National Patient Group Direction 
to allow the supply of naloxone 









A major focus of the national programme was to ensure that naloxone was provided 
to prisoners on-release because of their elevated risk of overdose and drug-related 
deaths within the weeks following liberation (Bird and Hutchison, 2003). 
 
On average, 7800 individuals are incarcerated within Scotland’s prisons daily (Scottish 
Government, 2015) and a third of those entering prison test positive for opiates at 
reception (Scottish Prison Service, 2014). 
 
Training is offered to people with a history of opiate use, and is provided by NHS staff, 
during their sentence, often within the 6 weeks prior to release. A naloxone kit is 
placed in their personal belongings by reception staff which is handed to people at the 
point of release (Horsburgh and McAuley, 2017). 
 
In addition, Scottish Drugs Forum has delivered ‘peer education’ training to numerous 
groups of prisoners across Scotland to allow them to train others within the prison. 
This approach has reportedly increased the acceptability of naloxone within the 
Scottish prison estate and undoubtedly assisted the staff to increase the number of 
kits provided. 
 
In the latest national naloxone report, a cumulative total of 4,343 THN kits were 
issued in prisons in Scotland from 2011/12 to 2015/16 (Information Services Division, 
2016b). 
 
More recently, training was provided to almost 300 night staff prison officers to give 
them the skills to identify an overdose and respond with naloxone. This is currently 
in the process of being approved by the Scottish Prison Service and awaiting a launch 
date. This training took place due to the fact that there is no nursing cover overnight 
in Scottish prisons and by providing officers with naloxone this will save valuable time 
while waiting for an ambulance to arrive. 
Practical steps 
The aim of the prison naloxone programme is to train prisoners in overdose preven- 
tion, intervention and naloxone during their sentence and to provide them with na- 
loxone-on-release. It is delivered by NHS staff and peers, facilitated by the Scottish 
Prison Service. 
 
There are many steps along the ‘prisoner journey’ through their sentence where they 
have access to training. The steps below describe some of the potential barriers and 
solutions to each phase. 
 
Reception 
This is where the prisoner is checked in when they arrive at the prison and a drug test 
will be taken by health care staff. If they have a positive test for opiates they should 
be informed of the naloxone programme and their interest noted in their file. If the 






This is not always the best time to introduce an intervention that will only be available 
on release. The person will undoubtedly have mainly other things on his mind. 
 
There is a change that they are not informed of the programme, it is not recorded or 




Ensure there are multiple opportunities for training throughout their sentence. 
 
Induction 
The induction programme is offered to all prisoners within the first few days of their 
sentence. In some establishments it is also peer delivered and in many the naloxone 
programme is included in this information session. Interest in the training is again not- 




Induction is not mandatory so people may not attend. Their interest in the training 




Ensure there are multiple opportunities for training throughout their sentence. 
Training 





These programmes are not mandatory so people may not attend. They also may be 




Ensure there are multiple opportunities for training throughout their sentence (the 
length of time prior to release is not the most important factor). 
Referrals 
During the person’s sentence, they can also self refer for training at any point – they 
may have seen a poster, read a leaflet, been told about it by a peer or by a family 
member/friend at a visit. 
 
Training delivery 






Organising trainers and participants to be in the same place at the same time was 
problematic. 
 
Prisoners had competing priorities – work, gym, visits etc. 
 
Prison officers were required to escort people to training which reportedly did not al- 
ways happen due to prisoners refusing on the day. 
 
Staff shortages or availability was an issue. 
 
Groups are not always suitable in a prison environment, particularly with the subject 




Training is now mostly delivered as a brief intervention over 10-15 minutes. 
 
One member of staff or a naloxone peer trainer delivers this – can be done in clinics, 
as part of other appointments or on the halls. 
 
The nursing staff then delivers the naloxone kit to the reception area to be placed 




The timing for this training can be problematic – if someone is trained a year before 
they are released, the kit needs to be put in their valuable property nearer that time. 
People are often released early from court before there has been a chance to put the 
kit in their valuables. 
 
Reception staff are not always informed of what naloxone is and may not realise the 




It is imperative that prison officers are given awareness sessions on naloxone. Not 
only so that they know what it is themselves but also so that they are able to answer 
questions from prisoners and encourage them to leave with it. 
 
Find a mechanism to ensure that the kit is placed in the valuables in plenty of time 
prior to court appearances, early release etc. 
 
Release day 




The kit has not been placed in the valuables. The person is unlikely to wait until it can 
be delivered at this point. 
 




it. This may be because the person has said they will no longer be using drugs and 
taking naloxone may be seen as contradictory. Or they may not wish to be seen as 




Ensure the kit is securely in the valuable property prior to release. 
 
Involve peers at this stage – a great example was in one of the Scottish prisons where 
naloxone peers were given a job that involved being at the reception area to ensure 
people left with their kits. 
 
The overwhelming majority of barriers have been operational. Systems and standard 









Scottish Drugs Forum introduced an innovative Naloxone Peer Education Programme 
in 2012, which continues to be implemented across Scotland to date (Scottish Drugs 
Forum, 2012). 
 
Peer educators are recruited from a variety of services in the community, most have 
a history of using drugs but in some cases, they are family members who have lost a 
son or daughter to an overdose. 
 
Peer educators are trained by SDF over four days focusing on different components of 
the skills and knowledge required to carrying out brief interventions in the community 
and are supported by face-to-face meetings on a monthly basis. 
 
Local support is provided by a named service lead in the area, with meetings planned 
on a regular basis with peers to discuss any training or personal issues that arise. 
Support as a group or 1-1 is then offered to people depending on the issues raised. 
Peer educators have, to date, provided thousands of hours of their own time to help 
increase the awareness and supplies of naloxone throughout Scotland with several 
thousand people now having been trained by a naloxone peer educator. 
 
In 2015, new regulations regarding the supply of naloxone, means that people 
employed or engaged in the provision of drug treatment services can provide it to 
anyone who may witness an overdose without the need for a prescription. This impor- 
tant change means that in addition to nurses and pharmacists, other people undertak- 
ing roles within drug treatment services can also make supplies of naloxone, such as 
volunteers. 
 
In August 2017, the UK’s first naloxone peer supply model was launched in Glasgow 
(Scottish Drugs Forum, 2017). 
 
It is hoped that the volunteers will contribute to increasing the availability of naloxone 
within the community so that it is more likely to be present when an overdose occurs, 
and the project will also provide additional skills and opportunities for the volunteers 
themselves. 
 
The newly established group will first target Recovery Communities in Glasgow, then 
move to supported accommodations, residential and community programmes, as well 
as aiming to reach people at risk in the streets of Glasgow who may be homeless or 
roofless and not currently engaged with services. Through adding the supply element 
to the current peer naloxone training, the model aims to be more effective in reaching 
these at-risk populations. 
 
The Peer Supply Model will be evaluated and if deemed a success, the model will be 
implemented in other Health Boards across Scotland. 
 
Within the first 3 months of operating, peers had supplied over 300 take-home 









The primary outcome for the effectiveness of the Scottish naloxone programme was to 
show a reduction in the number of opioid-related deaths within 4 weeks of liberation 
from prison. 
 
These deaths decreased by 36% from 9.8 to 6.3% during the evaluation period. It 
was estimated that having issued nearly 12,000 naloxone kits during 2011–13, Scot- 
land’s national naloxone programme may have prevented 42 prison release opioid-re- 
lated deaths. 
 
The secondary outcome was to show a reduction in the number of opioid-related 
deaths following hospital discharge and in contrast, the national naloxone programme 
had little apparent effect in this area (Bird et al. 2016). 
 
It should be noted that hospitals were not targeted as an essential naloxone supply 
route in the same way that prisons were. There are only a small numbers of hospitals 
across Scotland currently providing take-home naloxone via the hospital setting. 
Unfortunately over the course of the programme, drug-related deaths as a whole have 
continued to increase. 
 
Naloxone has been used thousands of times to reverse potentially fatal opiate-related 
overdoses so it is realistic to suggest that the number of deaths may have been much 
higher had naloxone not been available. 
 
Depending on our definition of effectiveness, there are other ways to look at the 
impact of the Scottish programme. 
 
From a treatment provider perspective – the introduction of the national programme 
made it more likely for practitioners to have conversations with people attending their 
service about the risks of overdose and how to respond. In a culture of what is often 
seen as ‘punitive’ type services, the programme offered a way to break down barriers 
and improve relationships with the client group. 
 
Providing naloxone is a very powerful message, indicating that it matters whether the 
individual lives or dies. 
 
The programme has succeeded in normalising the provision of naloxone to people who 
use drugs, their family members and now anyone else likely to witness an overdose, 
and is addressing stigma by doing so. 
 
Despite all of the above, naloxone is not present where all overdoses are occurring 









Police Scotland is not currently involved or accepting of the use of naloxone by their 
staff. Incidentally, police are very often first on the scene when an overdose occurs 
and therefore in a prime position to respond effectively with naloxone. One of the 
reasons used to justify this lack of acceptance is due to the product being injectable. 
In light of this it is hoped that in 2018 we will have access to an intranasal formulation 
which will assist in these discussions, which are still currently ongoing regardless. 
 
General Practitioners are well placed to be prescribing naloxone to people who may 
not be in contact with traditional drug services as many GPs prescribe opiate replace- 
ment therapy. It has been difficult to engage GPs in the programme, despite what 
previously appears to have been a potential will for them to do so (Pflanz-Sinclair et 
al. 2013). 
 
The Scottish Ambulance Service is another organisation that could have a key role in 
the distribution of naloxone when they attend non-fatal overdoses. Many people do 
not go with the paramedics to hospital and can be at risk of further overdose. This is a 
perfect opportunity to offer some brief training and provision of naloxone kits. 
 
Due to the regulation change in 2015, 3rd sector organisations can now provide 
naloxone, however many areas are not taking advantage of this change. 
 
Prison supply of naloxone has been variable across the estate and therefore could be 
better embedded to be more effective. 
 
Finally, the role of peers in the programme could be broadened to have more supply 
networks across the country which would greatly enhance the distribution to people 









The following guidance is based on the experience and learning from the Scottish 
National Naloxone Programme. 
 
Investigate the legal situation for providing naloxone to people who use drugs and others 
likely to witness an overdose. 
 
 
Identify project lead – this person will be responsible for managing and coordinating the 
implementation of the THN programme. 
 
 
Identify key partners – could include the following; relevant govt dept, prison headquarters, 
prison operations, prison healthcare, prison pharmacy, data collection dept, people who use 




Establish Working Group – this group will have multi-agency responsibility for the 
strategic coordination of the programme. 
 
 
Determine funding stream – main cost will be for the product itself and consideration 
should be given to additional staff required for the implementation phase (project lead 
and training leads). 
 
 
Identify suitable product – this should be in line with the legal framework of each country and 
affordability based on budget. 
 
 
Devise data collection model – consideration should be given to how this can be done 
in the least time-consuming manner for practitioners (example of Scottish system in 
appendix). Data should be collected on number of kits distributed, whether it is a first 
supply or a repeat supply (if it is a repeat supply, what is the reason for this – used on 
someone, used on themselves by another, lost, confiscated, other), demographics. You may 
also wish to collect ‘postcode’ data to identify the area the person receiving THN will be 
released to, if known. 
 
In Scotland, this data is provided to managers on a quarterly basis which allows for 




Establish supply mechanisms – consider the easiest method for opportunistic, unplanned 








Identify ‘master’ trainer – this person(s) will be responsible for training the workforce as 
trainers. They should have an excellent knowledge of overdose prevention, intervention 
and naloxone. They should read good quality information and receive some training 
themselves to ensure they are fully equipped to deliver. 
 
 
Devise training plan–identify those who will require training. The master trainer(s) should 
deliver ‘training for trainers’ to staff who will be training those likely to witness an 
overdose. Anyone can be trained as a trainer and can then also go on to deliver awareness 
sessions. The main ‘training for trainers’ should remain the responsibility of the master 




Design peer education model – it would be sensible to have a ‘go-to’ model that could be 
adapted to local needs if necessary. 
 
 




Communication – ensure that all partners, particularly those who will have a role in the 
delivery, are aware of the programme from the development stage so that people can 
prepare and feel part of it. 
 
 
Deliver training – training should be delivered once all of the practical processes are in 
place so that once a staff member has received training they can immediately start to 




Monitor programme – the working group should continue to meet once the programme is up 









Identify lead – this person will be part of the staff team and responsible for coordinating the 
programme inside the prison by ensuring barriers are addressed, data is being collected 
and that the programme is being delivered as intended. 
 
 
Identify lead for peer involvement – this will be a different person from the overall lead. It 
should be someone who is already involved in delivering programmes to prisoners and has 
a good reputation and relationship with prisoners. In Scotland, this was always an officer 
from the Scottish Prison Service rather than the health service. 
 
Standard Operating Procedures (SOPs) – SOPs should be in place detailing all of the 
operational aspects of the programme such as who will deliver training, how it will be 
recorded, where the naloxone will be stored and responsibilities for ensuring it is 




Paperwork – should be in place for recording training and monitoring data. 
 
 
Materials – leaflets, information cards and posters should be circulated around the prison 
and also provided to people following training. Consideration should also be given to the 
provision of certificates to those who complete the training. 
 
 
Devise a staff training plan – identify key staff to be trained as trainers and coordinate 
attendance for training. 
 
 
Attend staff training – all staff identified must attend the ‘training for trainers’ course delivered 
by the master trainer(s) before training people likely to witness an overdose. Following this, 




Identify prisoners for roles as peer educators – tips and guidance for this are provided in the 
section in chapter 10. 
 
 
Train peer educators – lead for peer involvement should arrange training for peers based 
on the programme that has been developed in advance. 
 
 
Deliver training – this should be opportunistic, brief and delivered in a variety of settings. It 
should be normalised and discussed at any opportunity. It may also be reasonable to have 































































Naloxone Training for Trainers (to be delivered by master trainer)  
This course should provide an overview of drug-related deaths (DRDs) nationally and 
locally with an emphasis on overdose prevention, intervention and naloxone. 
 
It should explore the causes of DRDs, risk factors, high risk times, myths and how to 
identify the signs and symptoms of an overdose. 
 
There should be a focus on naloxone, its actions, kit assembly and administration with 
specific attention to the inclusion of naloxone in basic life support. 
 
The course should also include an element of adult learning and teaching, providing 
people with the skills to deliver group sessions and brief interventions. 
 
Following the course workshops and practical skills training, participants should feel 
confident in identifying an overdose and intervening with naloxone which may be 
available for use in an emergency situation within the prisons. 
 
Participants should also be in a position to offer training on overdose and naloxone to 
people likely to witness an overdose, to encourage the uptake of take-home naloxone 




By the end of the session participants should; 
 
- Have a clear understanding of the evidenced based overdose prevention and 
naloxone messages 
- Clearly identify and communicate the observable signs/symptoms of a de- 
pressant overdose and respond accordingly 
- Be equipped with the skills and knowledge to manage an overdose 
emergency and answer questions from prisoners on naloxone 
- Have a much greater understanding of the THN Programme and its impor- 
tance to assist in the reduction of DRDs 








Example from Scotland: Training for Trainers (T4T) was initially delivered over 2 days 
but often reduced to 1 day due to restrictions of staff attendance. It is now delivered 
over 1 day but only due to the fact that SDF has other courses on DRDs that duplicate 





Generally delivered over 1.5-3 hours and are aimed at those who may need to re- 
spond to an overdose but will not be training people in the use of naloxone. 
 
Awareness sessions are a condensed version of the T4T, without the adult learning 








Peer Naloxone Education Programme 
 
(Training prisoners as trainers to deliver the intervention to others within the prison) 
In Scotland, this is a four day community based course (usually delivered over 3 
weeks) followed by six meetings (4-6 weekly) to consolidate learning. 
 
In the community, it would be as follows: 
 
Day One: Drug Awareness, with a strong emphasis on attitudes, values and stigma. 
 
Days Two and Three: Naloxone Training for Trainers course (as staff training). 
 
Day Four: Theory and Practical, exploring the benefits and challenges of peer educa- 
tion plus practical strategies for delivering training. 
 
This training not only enables peers to deliver naloxone training but also provides 
them with valuable skills to support their own personal development. 
 
In the prison environment it has been condensed to meet the needs of the prison 
regime. Prisoners receive the 2 days naloxone training for trainers first, followed by 
6 meetings that incorporate the training delivered on days 1 and 4 in the 
community. 
 
Learning Outcomes from Days 1 and 4 
 
Topics covered from both days 
 
- Drug harms 
- Drug groups, effects and their legal status 
- A brief history of drugs 
- Attitudes and values 
- Treatment options 
- What is peer education? 
- Advantages and Disadvantages of peer education 
- Peer led approaches 
- Peer information and education 
- Aggression-signs and de-escalation 
- Brief interventions 
- Facilitation skills 
- Managing nerves 
- Challenging situations 
 
By the end of the 6 follow up sessions participants will be able to: 
 
- Identify and explore values and attitudes around specific drugs 
- Recall different drug groups, effects and legal status 




- Identify the many reasons why people use drugs 
- Recall the principles behind peer education and identify the benefits and 
drawbacks 
- Demonstrate an understanding of the different types of peer-led approaches 
- Recall skills in managing awkward or challenging situations and behaviours 
during training 
- Name the main points of facilitating and co-facilitating a group training session 
- Plan a naloxone awareness session. 
 
Peer educators are supported by prison staff and health staff to deliver brief interven- 
tions in the prison. Staff is then able to ensure that a supply of naloxone is put in a 
prisoner’s personal property for their release. 
 
Tips for a Prison Peer Education Naloxone Programme 
(delivered by prisoners) 
 
- Promote the training for trainers well in advance 
- Provide a named member of staff as the regular contact for all peers 
- Provide regular support sessions and progress meetings with peers 
- Have all staff involved at the beginning of setting up a programme, i.e. prison 
staff, health staff etc. 
- Incentivise the training for prisoners 
- Allow all prisoners to apply for a place on the programme 
- Promote brief interventions to deliver training (10-15 minutes) 
- Have an internal communication strategy i.e. Prison magazine, radio, TV 
Channel. 
- Recruit long term prisoners, who will be around for a while 
- Engage prisoners who may already have a reputation or influence in the pris- 
on estate (they are your motivators to other prisoners for the programme to 
be successful) 
- Proper recognition for individuals who are involved in delivering training, 
should be celebrated and encouraged 
- Create naloxone posts for prisoners as their prison job 
- Ensure peer educators have a clear structure to provide details of prisoners 








When delivering sessions to people likely to witness an overdose, a training session 
should include the following1: 
 
 
The most common drugs identified in a drug-related death (heroin, meth- 
adone, benzodiazepines & alcohol – all CNS depressant drugs) and the physical 
effects these drugs have (slow, shallow, irregular breathing, slow heart rate, 
feeling less alert, unconsciousness, poor memory, not feeling pain, lower body 
temp) 
The main causes of drug overdose (low tolerance, polydrug use, using too 
much, using alone, injecting drug use, purity levels) 
High risk times (release from prison, leaving rehab or hospital, recent detox, 
recent relapse, poor physical or mental health, recent life events, cash windfall, 
longer-term user, festive periods, weekends or holidays) 
The signs & symptoms of suspected opiate overdose (pinpoint pupils, breath- 
ing problems, skin/lip colour, no response to noise or touch, loss of consciousness) 
The common myths (don’t inflict pain, give other drugs e.g. stimulants, put in 
bath/shower, walk person around, leave person on own) 
Knows when to call for an ambulance (when person won’t wake with shout/ 
shake, status of person and location) 
Knows about the recovery position (person on side, airway open) 
Knows about rescue breathing and CPR (30 compressions, 2 breaths – one 
cycle of BLS) 
Knows when and how to administer naloxone (unconscious but breath- 
ing – admin when in recovery position then every 2-3mins, unconscious but NOT 
breathing – admin after one cycle of BLS then after every three cycles of BLS. Dose 
– 0.4mls into outer thigh muscle via clothing. Assembly of syringe) 
 
*this is based on doses of Prenoxad Injection 
Knows that naloxone is short acting (the effects of naloxone wear off after 
20-30 mins, possible that overdose may return) 
Knows the importance of staying with the person (do not let the person use 
any other drugs if they gain consciousness) 
This intervention should be more like a conversation than a training session. The 
trainer should not just read from the list but engage the person by listening to their 
experiences or knowledge of overdose and drawing on that information to cover the 
key points. 
                                       









1. Make ‘training’ brief 
 
- A quick ten minute conversation is enough to provide someone with the 
basic skills to save a life. Never underestimate the potential outcome of a 
brief intervention! 
 
2. Don’t tell someone to come back at a later date, just get it done! 
 
- Opportunistic conversations while you have the person there in front of you 
can be the difference between life and death. You don’t know if you’ll ever 
see this person again, make sure they’re equipped! 
 
3. Make sure the training and supply happens in the same place 
 
- Your programme will be much more successful if you can physically hand 
over the naloxone after the training. Adding in additional steps may mean 
many people do not end up with a supply. 
 
4. Involve peers! 
 
- Peers have instant credibility among the target group and hugely enhance 
the rate of distribution, particularly when they are also enabled to make the 
supplies. 
 
5. If someone refuses naloxone from you, you’re doing something wrong. 
Change your message. 
 
- The key part of any programme is about relationships. If you can show 
someone that you genuinely care about whether they (or their friends) live 
or die, then no-one will refuse the offer of naloxone from you. 
 
6. Be creative, don’t expect people to come to you 
 
- Outreach! Go to where the people are, or the services they frequent, and 
don’t rely on an appointment-based programme. 
 
7. Prioritise the supply to people who use drugs 
 
- People who use drugs are most likely to witness an overdose. This should 
always be where the most effort is placed. 
 
8. Make sure everyone on opioid agonist treatment has a supply 
 
- Everyone you see on OAT should automatically be receiving a supply. You 
are providing a powerful opiate, you should also provide the antidote. 
(Yes, treatment is a protective factor but this is about ensuring coverage 




9. Prioritise, normalise and standardise in all drug services 
 
- The biggest risk of death for your client group is accidental and preventable 
overdose. 
 
10. Always encourage and support people to talk about their experience of 
using naloxone 
 
- If someone has used naloxone to save a life - congratulate them! This may 
also have been a traumatic experience and they may need some support. 









Policy makers Practitioners 
 
Legal situation investigated 
Able to proceed legally 
Project lead identified 
Key partners identified 
Key partners contacted 
Working group established 
Funding stream confirmed 
Suitable product identified 
Data collection model developed 
Supply mechanisms confirmed 
Master trainer identified 
Training plan devised 
Peer education model developed 
Materials produced 
Communication strategy in place 
Training for trainers delivered 
Plan to monitor programme in place 
Naloxone lead identified 
Peer involvement lead identified 
Standard operating procedures in place 
Paperwork for monitoring in place 
Materials available 
Staff training plan in place 
Staff trained as trainers 
Prisoners identified for peer education 
Prisoners trained as peer educators 
Training rolled out to people likely to 
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Appendix 1   
 
One to One Naloxone Training Checklist 
 
Trainee Details 
Name DOB Address (inc. postcode) GP Name & Address 
    
 
The person must demonstrate an understanding of the following: Trainer 
Initials 
The most common drugs identified in a drug-related death (heroin, 
methadone, diazepam & alcohol – all CNS depressant drugs) and the 
physical effects these drugs have (slow, shallow, irregular breathing, slow 
heart rate, feeling less alert, unconsciousness, poor memory, not feeling pain, 
lower body temp) 
 
The main causes of drug overdose (low tolerance, polydrug use, using too 
much, using alone, injecting drug use, purity levels) 
 
High risk times (release from prison, leaving rehab or hospital, recent detox, 
recent relapse, poor physical or mental health, recent life events, cash windfall, 
longer-term user, festive periods, weekends or holidays) 
 
The signs & symptoms of suspected opiate overdose (pinpoint pupils, 
breathing problems, skin/lip colour, no response to noise or touch, loss of 
consciousness) 
 
The common myths (don’t inflict pain, give other drugs e.g. stimulants, put in 
bath/shower, walk person around, leave person on own) 
 
Knows when to call 999 (when person won’t wake with shout/shake, status of 
person and location) 
 
Knows about the recovery position (person on side, airway open)  
Knows about rescue breathing and CPR (30 compressions, 2 breaths – one 
cycle of BLS) 
 
Knows when and how to administer naloxone (unconscious but breathing – 
admin when in recovery position then every 2-3mins, unconscious but NOT 
breathing – admin after one cycle of BLS then after every three cycles of BLS. 
Dose – 0.4mls into outer thigh muscle via clothing. Assembly of syringe) 
 
Knows that naloxone is short acting (the effects of naloxone wear off after 
20-30 mins, possible that overdose may return) 
 
Knows the importance of staying with the person (do not let the person 
use any other drugs if they gain consciousness) 
 
The above trainee has demonstrated an understanding and awareness of opiate overdose, the use of 




Service Name & Address………………………………………………………………….................................... 






Please print initials and month birth (Jan-Dec) here e.g. SMJun - _ _/ _ _ _ 
 
Pre session evaluation 
 
Have you had any overdose awareness or overdose 
intervention training before? Yes or No 
 
If yes, Great!! Where/when was this?  
 
How confident do you feel about being able to manage 
an overdose situation? (I.e. knowing exactly what steps 






Do you feel skilled enough to get involved in an 
overdose situation? (i.e. the practical skills required to 





What would you say could be 3 most important things 





Have you ever witnessed an overdose? 




What do think the main drugs involved in overdoses or 






What behaviours do you think puts a person at most 
risk of overdose when taking drugs? 
 
When do you think a person is most at risk of 
overdosing? 
 
In your opinion, and on a scale of 1-10, how serious a 
problem are drug overdoses in Scotland? 








Overdose prevention, Intervention and Naloxone Test 
 
 
What vital function stops first when opiate 
overdoses cause death? 
 





Name three factors that increase the risk of 




What is the major difference in the action of 
heroin and methadone? 
 
What is the usual first dose (in ml’s) of 
naloxone, and how would you give it? 
 
How often/at what intervals would you repeat 
naloxone administration? 
 
Does cocaine use increase or decrease heroin 
OD risks? 
 
Why is it essential that an ambulance is called, 
even after naloxone has been given to opiate 
overdose casualty? 
 
What three pieces of harm reduction advice 





First Aid Questions 
What are the ‘four steps’ involved in getting 





Why are rescue breaths so important?  











Post session evaluation 
 
 
How confident do you feel about being able to manage 






Do you feel skilled enough to get involved in an 






What would you say were the 3 most important things 





Have you ever witnessed an overdose? 




What do think the main drugs involved in overdoses or 






What behaviours do you think puts a person at most 
risk of overdose when taking drugs? 
 









Overdose Awareness and Naloxone Training For Trainers (T4) 
 
To what extent did the training meet your needs? 
Please circle one of the following options. 
Fully 
Partially 




Please select numbers 1 to 5 for the following questions. 1 being poor and 5 being excellent 
The trainers style was  
The trainers subject knowledge was  
The presentations were  
The venue was  
The length/duration of the training was  
 
Will this training make you more effective in your role or post? If so, how? 
 
How useful was each component of the training? 
Please select numbers 1 to 5 for the following questions. 1 being poor and 5 being excellent 
Background presentation  
Demonstration of awareness session  
Basic facilitation/presentation/group work skills  
Naloxone Training  
Emergency Basic Life support  
 
Please let us have any additional comments or thoughts about the training day/s 
 
Finally, if you could assist us with completing an online evaluation at a later date please provide 
with a suitable email address (please print) and phone number. 
 





























To acknowledge that the above named person has completed 
 
OVERDOSE PREVENTION, INTERVENTION & NALOXONE 
TRAINING FOR TRAINERS 






















Course Title: Overdose Prevention, Intervention and Naloxone Awareness Session 
 












Trainer/venue 1 being poor & 5 being excellent Please tick; 
 
 1 2 3 4 5 
The trainer style was      
The trainer subject knowledge was      
The presentations were      
The venue was      











How useful was each component? 
 
 Not A little Fairly Very 
Background presentation     
Overdose prevention     
Naloxone awareness     


























































































Follow Up Interview/Report 
The following form should be used as a brief guide (prompt for further details) 
 
Before proceeding, establish whether the overdose was: 









Details of person providing information 
Name  
Date of birth  




Details of person who overdosed - 
Male/Female  Age  


















Substances involved (If known)  




Were you present when the person overdosed? Yes No 
If yes, how long did it take for them (from 
point of using) to overdose? 
 
What were the signs/symptoms of overdose?  
How many other people were present (Apart 
from you and the person who overdosed)? 
 
Date & place (include 





Sequence of Events - 
Naloxone administered? YES NO 
How many doses?  
If No, please provide reason 
Ambulance phoned? YES NO 
If No, please provide reason 
What information did you give the 
emergency call handler? 
 
Did the emergency call handler talk 
through the naloxone process? 
YES NO 
Any other comments? 
Recovery position? YES NO 
If No, please provide reason 
CPR Performed? YES NO 
If No, please provide reason 
Did you wait with the person who 
overdosed until help arrived? 
YES NO 
If No, please provide reason 






Did the person who overdosed 
attend hospital 
YES NO DON’T KNOW 
If No, please provide reason 
How long did you stay with the 
person who overdosed after the 
paramedics left? 
 
Did the Police attend? YES NO 
Details of any action taken 
 
 




Signed ……………………………(staff member) Date ……………………… 
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